Patents by Inventor Yun-Long Li

Yun-Long Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
    Publication number: 20240124463
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: January 9, 2023
    Publication date: April 18, 2024
    Inventors: Yun-Long Li, Xiaozhao Wang, Joseph Barbosa, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jincong Zhuo
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11905275
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: February 20, 2024
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Tricyclic fused thiophene derivatives as JAK inhibitors
    Patent number: 11851442
    Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: December 26, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
  • Heterocyclylamines as PI3K inhibitors
    Patent number: 11819505
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: July 18, 2022
    Date of Patent: November 21, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Brent Douty, Song Mei
  • BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20230159501
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: January 24, 2023
    Publication date: May 25, 2023
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • HETEROCYCLYLAMINES AS PI3K INHIBITORS
    Publication number: 20230121440
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: July 18, 2022
    Publication date: April 20, 2023
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, JR., Richard B. Sparks, Brent Douty, Chunhong He
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11591318
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: February 28, 2023
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Pyrrolotriazine compounds as TAM inhibitors
    Patent number: 11591338
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: February 28, 2023
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors
    Publication number: 20230002392
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Application
    Filed: January 13, 2022
    Publication date: January 5, 2023
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Heterocyclylamines as PI3K inhibitors
    Patent number: 11433071
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: September 6, 2022
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
  • Pyrimidinones as PI3K inhibitors
    Patent number: 11401280
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: August 2, 2022
    Assignees: Incyte Holdings Corporation, Incyte Corportion
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • BICYCLIC HETEROARYLAMINOALKYL PHENYL DERIVATIVES AS PI3K INHIBITORS
    Publication number: 20220177491
    Abstract: This application relates to derivatives of Formula I. and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K, and compositions and methods of treatment related thereto.
    Type: Application
    Filed: August 24, 2021
    Publication date: June 9, 2022
    Inventors: Yun-Long Li, Andrew P. Combs
  • USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS
    Publication number: 20220119393
    Abstract: The present application provides methods of treating PI3K? related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 30, 2021
    Publication date: April 21, 2022
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Song Mei, Brent Douty
  • USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS
    Publication number: 20220106318
    Abstract: The present application provides methods of treating PI3K? related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 30, 2021
    Publication date: April 7, 2022
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Song Mei, Brent Douty
  • Imidazotriaines and imidazopyrimidines as kinase inhibitors
    Patent number: 11261191
    Abstract: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: March 1, 2022
    Assignees: INCYTE HOLDINGS CORPORATION, INCYTE CORPORATION
    Inventors: Jincong Zhuo, Meizhong Xu, Chunhong He, Colin Zhang, Ding-Quan Qian, David M. Burns, Yun-Long Li, Brian Metcalf, Wenqing Yao
  • Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
    Patent number: 11229631
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: January 25, 2022
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Jun Pan, Anlai Wang, Ke Zhang, Wenqing Yao, Fenglei Zhang, Jincong Zhuo
  • TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20210387998
    Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: August 12, 2021
    Publication date: December 16, 2021
    Inventors: Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
  • Tricyclic fused thiophene derivatives as JAK inhibitors
    Patent number: 11161855
    Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: November 2, 2021
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
  • USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3K-DELTA RELATED DISORDERS
    Publication number: 20210332059
    Abstract: The present application provides methods of treating PI3K? related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: June 30, 2021
    Publication date: October 28, 2021
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Song Mei, Brent Douty
  • Pyrrolopyrimidine derivatives as TAM inhibitors
    Patent number: 11136326
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: October 5, 2021
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye